• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    6/5/23 1:09:08 PM ET
    $AGEN
    $AMED
    $AMRS
    $APRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $AGEN alert in real time by email

    Gainers

    • Sono Group N.V. (NYSE:SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.
    • Forza X1, Inc. (NASDAQ:FRZA) shares jumped 94.3% to $2.4299 after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!'
    • Chijet Motor Company, Inc. (NASDAQ:CJET) shares gained 73% to $6.63 after dipping around 33% on Friday. The stock is experiencing an upward trend in trading Monday, driven by post-IPO volatility subsequent to its debut listing on the NASDAQ on Friday.
    • CIRCOR International, Inc. (NYSE:CIR) surged 50.1% to $47.54 after the company announced an agreement to be acquired by KKR for $49 per share in cash.
    • Regencell Bioscience Holdings Limited (NASDAQ:RGC) gained 35.5% to $30.49.
    • Timber Pharmaceuticals, Inc. (NYSE:TMBR) rose 35% to $2.0139 following a positive decision from the FDA for its TMB-001 treatment.
    • Pasithea Therapeutics Corp. (NASDAQ:KTTA) climbed 30.8% to $0.5232. Lucy Scientific Discovery announced proposal to acquire Pasithea Therapeutics for $0.60 per share in cash and $0.25 per share in Lucy stock.
    • Dunxin Financial Holdings Limited (NYSE:DXF) gained 29.9% to $0.2671after gaining over 15% on Friday.
    • InnSuites Hospitality Trust (NYSE:IHT) surged 27.3% to $3.0040.
    • National CineMedia, Inc. (NASDAQ:NCMI) gained 27% to $0.38. National CineMedia announced new long-term advertising agreement with Regal Cinemas.
    • CXApp Inc. (NASDAQ:CXAI) rose 23.7% to $12.35.
    • Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) surged 20% to $1.8238.
    • Journey Medical Corporation (NASDAQ:DERM) gained 20% to $1.50.
    • CURO Group Holdings Corp. (NYSE:CURO) rose 18.8% to $1.8297.
    • BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) gained 17.7% to $2.0249 after the company signed a worldwide license agreement to develop an antibody for treatment of autoimmune and inflammatory diseases.
    • Getty Images Holdings, Inc. (NYSE:GETY) climbed 15.5% to $5.50.
    • WeWork Inc. (NYSE:WE) gained 14.7% to $0.2123.
    • Replimune Group, Inc. (NASDAQ:REPL) rose 14.6% to $21.77. Replimune presented RP1 data from the IGNYTE anti-PD1 failed melanoma cohort and RP2 Data in uveal melanoma at the ASCO.
    • TOP Financial Group Limited (NASDAQ:TOP) surged 14.3% to $8.21.
    • Amedisys, Inc. (NASDAQ:AMED) gained 14.2% to $90.79 after the company received an unsolicited proposal from Optum for $100 per share.
    • Blue Apron Holdings, Inc. (NYSE:APRN) rose 14.1% to $0.6047.
    • Scilex Holding Company (NASDAQ:SCLX) jumped 12.6% to $7.22.
    • Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) gained 11.8% to $15.22 after the company announced overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pretreated RANO-HGG evaluable patients in pediatric low-grade glioma trial.
    • Kaspien Holdings Inc. (NASDAQ:KSPN) shares climbed 11.8% to $0.3316. Kaspien recently announced a voluntary delisting from The Nasdaq Capital Market.
    • Bowlero Corp. (NYSE:BOWL) rose 11% to $12.88. Stifel maintained Bowlero with a Buy and raised the price target from $24 to $25.
    • Erasca, Inc. (NASDAQ:ERAS) jumped 10% to $3.18.
    • Clover Health Investments, Corp. (NASDAQ:CLOV) rose 9.3% to $0.9659.
    • Agenus Inc. (NASDAQ:AGEN) gained 9.1% to $1.7450. Agenus presented complete results for AGEN2373 at 2023 ASCO meeting.
    • ImmunoGen, Inc. (NASDAQ:IMGN) shares gained 5.9% to $15.22 after the company announced that ELAHERE demonstrated 35% reduction in the risk of disease progression or death vs chemotherapy in FRα-Positive platinum-resistant ovarian cancer.

    Losers

    • Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) shares dipped 85% to $1.06 after the company's Phase 3 REBUILD trial did not meet its primary endpoint.
    • Castle Biosciences, Inc. (NASDAQ:CSTL) fell 48% to $11.80. Baird, SVB Securities and Lake Street lowered their price targets on the stock.
    • Cyxtera Technologies, Inc. (NASDAQ:CYXT) fell 37.2% to $0.10 after the company said, pursuant to the previously disclosed Restructuring Support Agreement it reached with certain of its lenders holding over two-thirds of its outstanding term loan, the Company and certain of its subsidiaries have initiated a pre-arranged court-supervised process under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the District of New Jersey.
    • Mallinckrodt plc (NYSE:MNK) fell 28.6% to $1.75. Mallinckrodt is considering options including filing for bankruptcy again, according to the Wall Street Journal.
    • Yunji Inc. (NASDAQ:YJ) shares dropped 26.5% to $0.23. Yunji shares jumped over 50% on Friday after the company reported first-quarter financial results.
    • Universal Security Instruments, Inc. (NYSE:UUU) dipped 18.3% to $2.45.
    • Context Therapeutics Inc. (NASDAQ:CNTX) fell 18% to $1.0501.
    • EPAM Systems, Inc. (NASDAQ:EPAM) declined 17.7% to $213.50 after the company cut its second-quarter financial outlook.
    • Amyris, Inc. (NASDAQ:AMRS) dropped 16.2% to $0.7885. Amyris initiated strategic transformation program and secured funding to deliver the company's planned cost reduction target of approximately $250 million from cost of goods sold.
    • Comtech Telecommunications Corp. (NASDAQ:CMTL) dropped 13.7% to $10.64.
    • DMC Global Inc. (NASDAQ:BOOM) fell 13.6% to $15.65.
    • SunCar Technology Group Inc. (NASDAQ:SDA) declined 13.2% to $20.22.
    • Elevation Oncology, Inc. (NASDAQ:ELEV) dropped 12.8% to $3.0850. Wedbush maintained Elevation Oncology with an Outperform and raised the price target from $4 to $6.
    • Gannett Co., Inc. (NYSE:GCI) fell 12.7% to $1.9650.
    • Zumiez Inc. (NASDAQ:ZUMZ) declined 11.1% to $13.76. Zumiez recently posted a wider-than-expected quarterly loss.
    • IGM Biosciences, Inc. (NASDAQ:IGMS) dropped 10.9% to $12.11. Wedbush reiterated IGM Biosciences with an Outperform and maintained a $37 price target.
    • Endava plc (NYSE:DAVA) declined 10.8% to $45.97. Needham reiterated Endava with a Buy and maintained a $68 price target.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares fell 10.2% to $0.22 after gaining over 8% on Friday.
    • Cibus, Inc. (NASDAQ:CBUS) dropped 9.6% to $24.40.
    • SHL Telemedicine Ltd. (NASDAQ:SHLT) fell 9.1% to $11.55 after gaining 10% on Friday.
    • Minerva Surgical, Inc. (NASDAQ:UTRS) shares dropped 7.9% to $0.27 after surging over 46% on Friday.
    • Blueprint Medicines Corporation (NASDAQ:BPMC) fell 6.8% to $54.24. SVB Leerink downgraded Blueprint Medicines from Market Perform to Underperform and lowered the price target from $48 to $43.
    • PetMed Express, Inc. (NASDAQ:PETS) declined 5.5% to $14.79.

     

    Now Read This: Bitcoin Falls Below This Major Level; Pepe Becomes Top Loser

    Get the next $AGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGEN
    $AMED
    $AMRS
    $APRN

    CompanyDatePrice TargetRatingAnalyst
    Day One Biopharmaceuticals Inc.
    $DAWN
    3/10/2026$21.50Buy → Neutral
    H.C. Wainwright
    Aptera Motors Corp.
    $SEV
    3/9/2026$10.00Buy
    Alliance Global Partners
    Erasca Inc.
    $ERAS
    1/27/2026$16.00Outperform
    Mizuho
    Day One Biopharmaceuticals Inc.
    $DAWN
    1/13/2026$34.00Buy
    TD Cowen
    Erasca Inc.
    $ERAS
    1/7/2026$5.00Overweight
    Piper Sandler
    EPAM Systems Inc.
    $EPAM
    1/6/2026$220.00Hold
    Truist
    Endava plc
    $DAVA
    11/12/2025$12.00 → $9.00Buy
    Needham
    Endava plc
    $DAVA
    11/11/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $AGEN
    $AMED
    $AMRS
    $APRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Weston Daine Marc

    4 - Getty Images Holdings, Inc. (0001898496) (Issuer)

    3/27/26 4:30:23 PM ET
    $GETY
    Real Estate

    SEC Form 4 filed by Teaster Michael

    4 - Getty Images Holdings, Inc. (0001898496) (Issuer)

    3/27/26 4:30:18 PM ET
    $GETY
    Real Estate

    SEC Form 4 filed by Mikael Cho

    4 - Getty Images Holdings, Inc. (0001898496) (Issuer)

    3/27/26 4:30:20 PM ET
    $GETY
    Real Estate

    $AGEN
    $AMED
    $AMRS
    $APRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Day One Biopharmaceuticals downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Day One Biopharmaceuticals from Buy to Neutral and set a new price target of $21.50

    3/10/26 8:39:03 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on Aptera Motors Corp. with a new price target

    Alliance Global Partners initiated coverage of Aptera Motors Corp. with a rating of Buy and set a new price target of $10.00

    3/9/26 9:28:24 AM ET
    $SEV
    Auto Manufacturing
    Industrials

    Mizuho resumed coverage on Erasca with a new price target

    Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

    1/27/26 8:45:40 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGEN
    $AMED
    $AMRS
    $APRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ault Milton C Iii bought $118,668 worth of shares (20,000 units at $5.93) (SEC Form 4)

    4 - UNIVERSAL SAFETY PRODUCTS, INC. (0000102109) (Issuer)

    3/17/26 4:30:27 PM ET
    $UUU
    Electronic Components
    Technology

    Director Ault Milton C Iii bought $330,650 worth of shares (60,500 units at $5.47), increasing direct ownership by 17% to 1,400 units (SEC Form 4)

    4 - UNIVERSAL SAFETY PRODUCTS, INC. (0000102109) (Issuer)

    3/12/26 6:30:03 PM ET
    $UUU
    Electronic Components
    Technology

    Director Ault Milton C Iii bought $149,572 worth of shares (28,892 units at $5.18) (SEC Form 4)

    4 - UNIVERSAL SAFETY PRODUCTS, INC. (0000102109) (Issuer)

    3/9/26 6:00:08 PM ET
    $UUU
    Electronic Components
    Technology

    $AGEN
    $AMED
    $AMRS
    $APRN
    SEC Filings

    View All

    SEC Form 144 filed by National CineMedia Inc.

    144 - National CineMedia, Inc. (0001377630) (Subject)

    3/27/26 4:39:56 PM ET
    $NCMI
    Advertising
    Consumer Discretionary

    Universal Safety Products Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - UNIVERSAL SAFETY PRODUCTS, INC. (0000102109) (Filer)

    3/27/26 4:30:25 PM ET
    $UUU
    Electronic Components
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Zumiez Inc.

    SCHEDULE 13G/A - Zumiez Inc (0001318008) (Subject)

    3/27/26 2:25:47 PM ET
    $ZUMZ
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $AGEN
    $AMED
    $AMRS
    $APRN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

    Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

    4/24/24 12:52:43 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGEN
    $AMED
    $AMRS
    $APRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now ac

    3/27/26 10:15:00 AM ET
    $CLOV
    $LIVN
    $MBOT
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Biological Products (No Diagnostic Substances)

    Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026

    Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee on Cancer (AJCC) stages and T categories, identifying patients whose mortality risk is substantially higher or lower than staging alone would predictFRIENDSWOOD, Texas, March 27, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will present new data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27–31 in Denver, demonstrating that its DecisionDx-Melanoma test refines mo

    3/27/26 9:05:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Yunji Announces Second Half and Fiscal Year 2025 Unaudited Financial Results

    HANGZHOU, China, March 27, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced its unaudited financial results for the second half and fiscal year ended December 31, 20251. Second Half 2025 HighlightsTotal revenues in the second half of 2025 were RMB158.7 million (US$22.7 million), compared with RMB183.8 million in the same period of 2024. The change was primarily due to the Company's continued strategy to refine its product selection across all categories and optimize its selection of suppliers and merchants, together with a deliberate scale-back of the marketplace business.Repeat purchase rate2 in th

    3/27/26 6:00:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    $AGEN
    $AMED
    $AMRS
    $APRN
    Leadership Updates

    Live Leadership Updates

    View All

    Groupon Launches Board-Level Artificial Intelligence Committee and Appoints Amit Shah to Board of Directors

    Technology executive and AI entrepreneur to chair new committee as Company positions marketplace for the era of agentic commerceChicago, Illinois--(Newsfile Corp. - March 10, 2026) - Groupon, Inc. (NASDAQ:GRPN) today announced the appointment of Amit Shah to its Board of Directors, effective March 10, 2026, and the formation of a dedicated Artificial Intelligence Committee of the Board. Shah, a seasoned technology executive and AI entrepreneur, will serve as the Committee's inaugural Chair.With this action, Groupon becomes one of the first publicly traded consumer marketplaces to establish a board-level committee dedicated to artificial intelligence. The formation of the Committee reflects t

    3/10/26 4:15:00 PM ET
    $APRN
    $FLWS
    $GRPN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Other Specialty Stores
    Advertising

    Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

    FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company's new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility. Local, state and national elected officials are expected to join the event, underscoring the significance of Castle's i

    3/3/26 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Nexus Global Payments Appoints Technical Operator

    PayNet and NETS joint venture awarded contract to be Nexus Technical Operator, with support from Endava and AWS Nexus Global Payments (NGP) appoints Payments Network Malaysia (PayNet) and Network for Electronic Transfers Singapore (NETS) joint venture as the Nexus Technical Operator (NTO). This follows a competitive procurement process involving global bidders and marks a major milestone in building an interoperable global payments infrastructure. The evaluation of bidders considered technical capability, operational resilience, cost efficiency, and alignment with Nexus' vision for global interoperability. PayNet and NETS joint venture emerged as the preferred partner due to the proven

    2/9/26 6:21:00 AM ET
    $DAVA
    EDP Services
    Technology

    $AGEN
    $AMED
    $AMRS
    $APRN
    Financials

    Live finance-specific insights

    View All

    Yunji Announces Second Half and Fiscal Year 2025 Unaudited Financial Results

    HANGZHOU, China, March 27, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced its unaudited financial results for the second half and fiscal year ended December 31, 20251. Second Half 2025 HighlightsTotal revenues in the second half of 2025 were RMB158.7 million (US$22.7 million), compared with RMB183.8 million in the same period of 2024. The change was primarily due to the Company's continued strategy to refine its product selection across all categories and optimize its selection of suppliers and merchants, together with a deliberate scale-back of the marketplace business.Repeat purchase rate2 in th

    3/27/26 6:00:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

    Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for t

    3/25/26 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Context Therapeutics Reports Full Year 2025 Operating and Financial Results

    Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. "We believe 2025 was a year of significant progr

    3/23/26 4:16:40 PM ET
    $CNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGEN
    $AMED
    $AMRS
    $APRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Getty Images Holdings Inc.

    SC 13D/A - Getty Images Holdings, Inc. (0001898496) (Subject)

    11/22/24 5:10:10 PM ET
    $GETY
    Real Estate

    Amendment: SEC Form SC 13D/A filed by National CineMedia Inc.

    SC 13D/A - National CineMedia, Inc. (0001377630) (Subject)

    11/20/24 9:34:56 PM ET
    $NCMI
    Advertising
    Consumer Discretionary

    $AGEN
    $AMED
    $AMRS
    $APRN
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care